» Articles » PMID: 22267597

Adaptive Immunity Suppresses Formation and Progression of Diethylnitrosamine-induced Liver Cancer

Abstract

Background: Hepatocellular carcinoma (HCC) is a typical inflammation-associated cancer, but may also provoke antitumour immune responses whose significance and underlying mechanisms are incompletely understood.

Objective: To characterise immune responses in the diethylnitrosamine (DEN)-liver cancer mouse model.

Design: Tumour development and immune cell functions upon DEN treatment were compared between C57BL/6 wild-type (WT), chemokine scavenging receptor D6-deficient, B cell- (Igh6), CD4 T cell- (MHC-II) and T-/B cell-deficient (Rag1) mice. Relevance for human HCC was tested by comparing gene array results from 139 HCC tissues.

Results: The induction of premalignant lesions after 24 weeks and of HCC-like tumours after 42 weeks by DEN in mice was accompanied by significant leucocyte infiltration in the liver and upregulation of distinct intrahepatic chemokines (CCL2, CCL5, CXCL9). Macrophages and CD8 (cytotoxic) T cells were most prominently enriched in tumour-bearing livers, similar to samples from human HCC. Myeloid-derived suppressor cells (MDSC) increased in extrahepatic compartments of DEN-treated mice (bone marrow, spleen). The contribution of immune cell subsets for DEN-induced hepatocarcinogenesis was functionally dissected. In D6(-/-) mice, which lack the chemokine scavenging receptor D6, hepatic macrophage infiltration was significantly increased, but tumour formation and progression did not differ from that of WT mice. In contrast, progression of hepatic tumours (numbers, diameters, tumour load) was strikingly enhanced in T-/B cell-deficient Rag1(-/-) mice upon DEN treatment. When mice deficient for B cells (Igh6(-/-), μMT) or major histocompatibility complex II were used, the data indicated that T cells prevent initial tumour formation, while B cells critically limit growth of established tumours. Accordingly, in tumour-bearing mice antibody production against liver-related model antigen was enhanced, indicating tumour-associated B cell activation. In agreement, T and B cell pathways were differentially regulated in gene array analyses from 139 human HCC tissues and significantly associated with patients' survival.

Conclusions: Distinct axes of the adaptive immune system, which are also prognostic in human HCC, actively suppress DEN-induced hepatocarcinogenesis by controlling tumour formation and progression.

Citing Articles

Liver sinusoidal endothelial cells regulate the balance between hepatic immunosuppression and immunosurveillance.

Kremer K, Khammash H, Miranda A, Rutt L, Twardy S, Anton P Front Immunol. 2025; 15:1497788.

PMID: 39896805 PMC: 11782242. DOI: 10.3389/fimmu.2024.1497788.


Essential roles of B cell subsets in the progression of MASLD and HCC.

Petriv N, Suo H, Hochnadel I, Timrott K, Bondarenko N, Neubert L JHEP Rep. 2024; 6(12):101189.

PMID: 39611128 PMC: 11602976. DOI: 10.1016/j.jhepr.2024.101189.


Resistance against the development of diethylnitrosamine-induced hepatocellular carcinoma in female C3H mice: an experimental model.

Montagna D, Todero M, Postma G, Trigo R, Bernal A, Bustuoabad O Exp Anim. 2024; 73(4):399-411.

PMID: 39098024 PMC: 11534494. DOI: 10.1538/expanim.23-0149.


Lenvatinib targets STAT-1 to enhance the M1 polarization of TAMs during hepatocellular carcinoma progression.

Sun P, Li Z, Yan Z, Wang Z, Zheng P, Wang M BMC Cancer. 2024; 24(1):922.

PMID: 39080642 PMC: 11289911. DOI: 10.1186/s12885-024-12680-1.


Biological impact and therapeutic implication of tumor-associated macrophages in hepatocellular carcinoma.

Li D, Zhang T, Guo Y, Bi C, Liu M, Wang G Cell Death Dis. 2024; 15(7):498.

PMID: 38997297 PMC: 11245522. DOI: 10.1038/s41419-024-06888-z.


References
1.
Koebel C, Vermi W, Swann J, Zerafa N, Rodig S, Old L . Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 2007; 450(7171):903-7. DOI: 10.1038/nature06309. View

2.
Lee J, Chu I, Heo J, Calvisi D, Sun Z, Roskams T . Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology. 2004; 40(3):667-76. DOI: 10.1002/hep.20375. View

3.
Fu C, Turck C, Kurosaki T, Chan A . BLNK: a central linker protein in B cell activation. Immunity. 1998; 9(1):93-103. DOI: 10.1016/s1074-7613(00)80591-9. View

4.
Fruman D, Snapper S, Yballe C, Davidson L, Yu J, Alt F . Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85alpha. Science. 1999; 283(5400):393-7. DOI: 10.1126/science.283.5400.393. View

5.
Tacke F, Ginhoux F, Jakubzick C, van Rooijen N, Merad M, Randolph G . Immature monocytes acquire antigens from other cells in the bone marrow and present them to T cells after maturing in the periphery. J Exp Med. 2006; 203(3):583-97. PMC: 2118235. DOI: 10.1084/jem.20052119. View